BioVersys AG | Finanzwire

Basculer en Français

9475	Companies
185452	Keywords
117801	Articles
99309	Press releases

Home
Companies
BioVersys AG

BRIEF

published on 04/28/2025 at 07:05, 7 months 7 days ago

BioVersys to Host Virtual Event on BV100 Study for VABP

Virtual Event BioVersys AG BV100 Study VABP Treatment Carbapenem Resistance
PRESS RELEASE

published on 04/28/2025 at 07:00, 7 months 7 days ago

BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025
BioVersys AG to host virtual KOL event featuring Prof. David Paterson & Dr. Andrew Shorr on BV100 Phase 2 VABP study against CRAB. Register for insights on May 7, 2025

Virtual Event BioVersys AG Antibacterial Products Multidrug-resistant Bacteria Key Opinion Leaders
BRIEF

published on 04/08/2025 at 07:05, 7 months 27 days ago

BioVersys to Showcase BV100 Data at ESCMID Global 2025

Clinical Trial Antibiotic Resistance BV100 BioVersys ESCMID 2025
PRESS RELEASE

published on 04/08/2025 at 07:00, 7 months 27 days ago

BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025
BioVersys to present BV100 Phase 2 data at 35th ESCMID Global 2025. Oral presentation on positive VABP trial read-out & poster presentations on Acinetobacter baumannii & NTM data

Clinical Data BV100 Antibacterial Products BioVersys ESCMID Global 2025
BRIEF

published on 03/31/2025 at 07:05, 8 months 5 days ago

BioVersys Secures Chinese Patent for BV100 Technology

Chinese Market BioVersys AG BV100 Patent Acinetobacter Infections Rifabutin Formulation
PRESS RELEASE

published on 03/31/2025 at 07:00, 8 months 5 days ago

BIOVERSYS ANNOUNCES IMPORTANT BV100 PATENT GRANTED BY CHINESE PATENT OFFICE
BioVersys AG announces the granting of an important BV100 patent by the Chinese Patent Office, protecting novel drug candidate technology

Patent China BioVersys AG BV100 Antibacterial
BRIEF

published on 03/26/2025 at 07:05, 8 months 10 days ago

BioVersys Outlines 2024 Achievements and Financials

2024 Financials IPO Success BioVersys AG BV100 Trial Alpibectir Studies
PRESS RELEASE

published on 03/26/2025 at 07:00, 8 months 10 days ago

BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024
BioVersys AG reports corporate highlights and key financials for the full year 2024 including successful IPO on SIX Swiss Exchange, Phase 2 trial results, and financial activities

Financial Results Clinical Trials IPO Operating Income BioVersys AG
BRIEF

published on 03/19/2025 at 07:05, 8 months 17 days ago

First Patient Dosed in Alpibectir-Ethionamide TB Trial

Phase 2 Trial GSK Collaboration BioVersys Alpibectir-Ethionamide Tuberculosis
PRESS RELEASE

published on 03/19/2025 at 07:00, 8 months 17 days ago

FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-LINE TB DRUGS IN A 14-DAY PHASE 2 CLINICAL TRIAL
First patient dosed in 14-day Phase 2 clinical trial evaluating Alpibectir-Ethionamide with first-line TB drugs under BioVersys and GSK collaboration for pulmonary TB patients

GSK Phase 2 BioVersys Alpibectir-Ethionamide TB

Accesswire

Published on 12/05/2025 at 02:35, 10 hours 58 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 11 hours 3 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 12 hours 33 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 28 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 33 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 13:00, 33 minutes ago

Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 33 minutes ago

Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 28 minutes ago

Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 33 minutes ago

CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 1 hour 33 minutes ago

Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million

Les Echos

Published on 12/05/2025 at 08:45, 4 hours 48 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 19 hours 33 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 19 hours 48 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 19 hours 49 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 6 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE